Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTX NASDAQ:CTXR NASDAQ:ENTX NASDAQ:FLNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$0.58$1.95$0.55▼$3.62$53.29M1.613.58 million shs14.81 million shsCTXRCitius Pharmaceuticals$0.54$0.65$0.48▼$2.48$14.82M1.03265,774 shs122,894 shsENTXEntera Bio$1.65+1.3%$1.25$0.91▼$3.22$80.34M1.562.81 million shs415,882 shsFLNACassava Sciences$1.20$1.38$1.15▼$4.98$57.97M-0.72324,342 shs358,346 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics0.00%-8.21%-79.65%-76.33%-12.15%CTXRCitius Pharmaceuticals0.00%-1.17%-17.54%-20.63%-64.71%ENTXEntera Bio0.00%+36.45%+22.30%+65.10%-13.11%FLNACassava Sciences0.00%-1.64%-22.08%-28.14%-31.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTXContext Therapeutics$0.58$1.95$0.55▼$3.62$53.29M1.613.58 million shs14.81 million shsCTXRCitius Pharmaceuticals$0.54$0.65$0.48▼$2.48$14.82M1.03265,774 shs122,894 shsENTXEntera Bio$1.65+1.3%$1.25$0.91▼$3.22$80.34M1.562.81 million shs415,882 shsFLNACassava Sciences$1.20$1.38$1.15▼$4.98$57.97M-0.72324,342 shs358,346 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTXContext Therapeutics0.00%-8.21%-79.65%-76.33%-12.15%CTXRCitius Pharmaceuticals0.00%-1.17%-17.54%-20.63%-64.71%ENTXEntera Bio0.00%+36.45%+22.30%+65.10%-13.11%FLNACassava Sciences0.00%-1.64%-22.08%-28.14%-31.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTXContext Therapeutics 2.89Moderate Buy$6.17963.22% UpsideCTXRCitius Pharmaceuticals 2.25Hold$5.00825.93% UpsideENTXEntera Bio 2.00Hold$9.00445.12% UpsideFLNACassava Sciences 2.00Hold$5.00316.67% UpsideCurrent Analyst Ratings BreakdownLatest CTXR, ENTX, FLNA, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026CTXRCitius Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/24/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/16/2026CNTXContext Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $4.005/26/2026FLNACassava Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/19/2026CTXRCitius Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026CTXRCitius Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.004/27/2026ENTXEntera Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $9.004/22/2026FLNACassava Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026ENTXEntera Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/A$4.29 per shareN/AENTXEntera BioN/AN/AN/AN/A$0.29 per shareN/AFLNACassava SciencesN/AN/AN/AN/A$1.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)CTXRCitius Pharmaceuticals-$37.43M-$2.13N/AN/AN/AN/A-61.09%-35.36%8/11/2026 (Estimated)ENTXEntera Bio-$11.44M-$0.27N/AN/AN/AN/A-83.31%-70.83%8/14/2026 (Estimated)FLNACassava Sciences-$90.97M-$1.61N/AN/AN/AN/A-53.90%-34.20%N/ALatest CTXR, ENTX, FLNA, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026CTXRCitius Pharmaceuticals-$0.2808-$0.95-$0.6693-$0.95$10.23 millionN/A5/8/2026Q1 2026ENTXEntera Bio-$0.08-$0.07+$0.01$0.07N/AN/A5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTXContext TherapeuticsN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTXContext TherapeuticsN/A8.968.96CTXRCitius PharmaceuticalsN/A0.580.16ENTXEntera BioN/A7.937.93FLNACassava SciencesN/A2.192.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTXContext Therapeutics14.03%CTXRCitius Pharmaceuticals16.88%ENTXEntera Bio14.11%FLNACassava Sciences38.05%Insider OwnershipCompanyInsider OwnershipCNTXContext Therapeutics4.80%CTXRCitius Pharmaceuticals4.99%ENTXEntera Bio10.57%FLNACassava Sciences4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionableCTXRCitius Pharmaceuticals2027.45 million26.08 millionOptionableENTXEntera Bio2049.29 million44.08 millionOptionableFLNACassava Sciences2048.31 million46.09 millionOptionableCTXR, ENTX, FLNA, and CNTX HeadlinesRecent News About These CompaniesData I/O And 2 Other Promising Penny Stocks To WatchMay 29, 2026 | finance.yahoo.comCassava Sciences and former execs, facing SEC charges for misleading claims, agree to finesMay 29, 2026 | statnews.comSFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7, 2026 | finance.yahoo.comFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateMay 7, 2026 | globenewswire.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | finance.yahoo.comFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIMay 5, 2026 | globenewswire.comFilana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | finance.yahoo.comFilana leaves Cassava roots behind amid branch into epilepsyMarch 11, 2026 | fiercepharma.comFCassava Sciences to rebrand to Filana TherapeuticsMarch 10, 2026 | seekingalpha.comCassava Sciences Announces Name Change to Filana Therapeutics, Inc.March 10, 2026 | finance.yahoo.comCassava Sciences Rebrands as Filana Therapeutics, Updates TickerMarch 10, 2026 | tipranks.comWhy Cassava Sciences, Inc.’s (SAVA) Stock Is Up 6.02%February 24, 2026 | aaii.comACassava says DoJ has ended probe into research misconductFebruary 20, 2026 | seekingalpha.comCassava Announces Closure of U.S. Department of Justice InvestigationFebruary 20, 2026 | finance.yahoo.comCassava Sciences stock rises after DOJ closes investigationFebruary 20, 2026 | za.investing.comCassava Sciences gains as DOJ ends probe into research misconduct claimsFebruary 20, 2026 | msn.comCassava Sciences says US DOJ has closed investigation into companyFebruary 20, 2026 | msn.comCassava Announces Closure of U.S. Department of Justice InvestigationFebruary 19, 2026 | markets.businessinsider.comCassava Sciences And 2 Other Promising Penny StocksFebruary 11, 2026 | finance.yahoo.comCassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s DiseaseJanuary 13, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTXR, ENTX, FLNA, and CNTX Company DescriptionsContext Therapeutics NASDAQ:CNTX$0.58 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.59 +0.01 (+2.41%) As of 08:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Citius Pharmaceuticals NASDAQ:CTXR$0.54 0.00 (0.00%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$0.55 +0.01 (+1.85%) As of 07:33 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Entera Bio NASDAQ:ENTX$1.65 +0.02 (+1.29%) Closing price 06/26/2026 03:58 PM EasternExtended Trading$1.60 -0.06 (-3.39%) As of 08:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Cassava Sciences NASDAQ:FLNA$1.20 0.00 (0.00%) As of 06/26/2026 04:00 PM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/22 - 06/26 Rocket Lab's NASA Win Tests Key Support After Sharp Pullback Winnebago Misses Estimates, But Surges 14% After Earnings 3 ETFs Pairing Market-Beating Returns With High Dividend Yields BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone SpaceX Has Real Value—But These 3 Stocks Have Better Odds Right Now Fabrinet Is Becoming a Quiet Winner in the AI Optics Buildout 3 Stocks That Could Benefit as the Robotaxi Race Heats Up Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
